Literature DB >> 31442521

Frequency and extent of cytokeratin expression in paraganglioma: an immunohistochemical study of 60 cases from 5 anatomic sites and review of the literature.

Josephine Kamtai Dermawan1, Sanjay Mukhopadhyay2, Akeesha Alia Shah2.   

Abstract

The absence of cytokeratin expression in paraganglioma helps to differentiate it from other neuroendocrine neoplasms such as carcinoid tumor. Although rare cytokeratin positive paragangliomas have been reported, there are no large systematic studies of this phenomenon. The aim of this study was to determine the frequency and extent of cytokeratin expression in paragangliomas using a large cohort of cases from multiple anatomic sites. Immunohistochemical staining for keratin AE1/AE3 (mouse monoclonal, MAB3412; Millipore) and CAM 5.2 (mouse monoclonal, 349 205; Becton-Dickinson) was performed on whole-tissue sections from 60 resected paragangliomas from the head and neck (36), thorax (10), abdomen (8), intradural/epidural spine (5) and bone, left iliac (1). Cytokeratin expression was identified in only 2/60 (3.3%) cases. One was a mediastinal paraganglioma with moderate to strong expression of keratin AE1/AE3 and CAM 5.2 in <5% tumor cells. The other was a lumbar intradural paraganglioma positive for CAM 5.2 (moderate to strong, 80% of tumor cells) but negative for keratin AE1/AE3. All other paragangliomas (58/60, 96.7%) were negative for keratin AE1/AE3 and CAM 5.2. This study - the largest series of cytokeratin-stained whole-tissue sections of paragangliomas to date - supports the dictum that most paragangliomas are cytokeratin negative. Rare exceptions may be site-related.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytokeratin; Immunohistochemistry; Keratin; Lumbar; Mediastinal; Paraganglioma

Mesh:

Substances:

Year:  2019        PMID: 31442521     DOI: 10.1016/j.humpath.2019.08.013

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

Review 1.  Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.

Authors:  Ozgur Mete; Sylvia L Asa; Anthony J Gill; Noriko Kimura; Ronald R de Krijger; Arthur Tischler
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

2.  Immunohistochemical distinction of paragangliomas from epithelial neuroendocrine tumors-gangliocytic duodenal and cauda equina paragangliomas align with epithelial neuroendocrine tumors.

Authors:  Divya Mamilla; Irena Manukyan; Patricia A Fetsch; Karel Pacak; Markku Miettinen
Journal:  Hum Pathol       Date:  2020-07-12       Impact factor: 3.466

Review 3.  Diagnostic Challenges in the Cytology of Thymic Epithelial Neoplasms.

Authors:  Jonathan Willner; Fang Zhou; Andre L Moreira
Journal:  Cancers (Basel)       Date:  2022-04-15       Impact factor: 6.575

Review 4.  Preoperative Diagnosis of Abdominal Extra-Adrenal Paragangliomas with Fine-Needle Biopsy.

Authors:  Ilias P Nikas; Angela Ishak; Mousa M AlRawashdeh; Eirini Klapsinou; Athanasia Sepsa; George N Tzimas; Dimitrios Panagiotakopoulos; Dimitrios Papaioannou; Charitini Salla
Journal:  Diagnostics (Basel)       Date:  2022-07-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.